Topical clascoterone vs. adapalene for mild-to-moderate acne in teens and young adults
Official title: Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris
Run by Pak Emirates Military Hospital · NCT07883538 · Data updated 2026-11-12
This trial tests whether clascoterone 1% cream works as well as adapalene 0.1% cream for treating mild-to-moderate acne in people aged 12–55.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 55 Years |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Pak Emirates Military Hospital Academic / other |
| Locations | 1 site (Rawalpindi, Punjab Province) |
| Status | Recruiting |
| Started | October 8, 2026 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07883538 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are males and females aged 12–55 with clinically diagnosed mild-to-moderate acne who agree to follow the treatment and follow-up visits.
✕Probably not a fit
Some participants may not experience clear or almost clear skin despite treatment, or may have adverse effects that limit benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial compares two topical acne treatments, clascoterone 1% cream applied twice daily and adapalene 0.1% cream applied once daily at night, over 12 weeks in patients with mild-to-moderate acne vulgaris. Participants will be evaluated at baseline, 4, 8, and 12 weeks using the Investigator's Global Assessment and lesion counts to determine treatment success (IGA 0 or 1). The study aims to determine which cream provides better skin clearance and safety in a dermatology outpatient setting in Rawalpindi, Pakistan. Both groups receive standard skincare advice, including gentle cleansing, moisturizers, sun protection, and avoidance of lesion picking. The trial will enroll 130 participants aged 12–55 years who meet the eligibility criteria.
Why it matters
Potential benefit: If clascoterone proves as effective or better than adapalene, patients may have an alternative topical option with a similar safety profile.
How similar studies have gone: Previous studies with clascoterone and with adapalene individually show activity in acne; direct head-to-head data are limited, making this comparative trial informative.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with clinically diagnosed mild-to-moderate acne vulgaris. 2. Patients willing to use the assigned treatment and attend scheduled follow-up visits. 3. Any gender between the ages of 12 and 55. Exclusion Criteria: 1. Acne-like eruptions caused by drugs or another identifiable condition. 2. Recent topical or systemic anti-acne treatment that may affect assessment of the study treatment. 3. Pregnancy or breastfeeding as both these treatments are contraindicated. 4. Known allergy or hypersensitivity to clascoterone, adapalene or their formulation components.
Where it's running
-
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan Recruiting
Study contacts
- Principal investigator: dr Zeshan akhtar, MBBS — Pak Emiratres MIlitary Hospital Rawalpindi Pakistan
- Study coordinator: Dr Zeshan Akhtar, MBBS
- Email: zeshanakhtar367@gmail.com
- Phone: +923215767900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nadifloxacin Plus Tretinoin vs Clindamycin Plus Tretinoin for Mild-to-Moderate Acne
This study tests whether nadifloxacin with tretinoin cream works better than clindamycin with tretinoin cream for adults with mild-to-moderate acne.
-
Denifanstat vs placebo for moderate to severe acne in teens and adults
This study tests whether denifanstat works safely to improve acne in people 12 and older, compared with a matching placebo.
-
Facial skin microbiome changes during isotretinoin in moderate-to-severe acne
This study tests how the facial skin microbiome changes in people with moderate-to-severe acne who are treated with isotretinoin, and compares them with healthy individuals.
-
Prevalence of PMOS in women with acne at Sohag University Hospital
This study tests how common polyendocrine metabolic ovarian syndrome (PMOS) is among women with acne who are seen at Sohag University Hospital.
-
Hormonal profiles and isotretinoin response in adult women with acne
This study tests whether baseline hormones (DHEAS, FSH, and LH) help predict how adult women with acne will respond to systemic isotretinoin.
-
RF treatment vs topical therapy for facial acne vulgaris
Adults with mild-to-moderate inflammatory facial acne will try either a three-session radiofrequency treatment or a daily adapalene-benzoyl peroxide gel, to see which reduces acne lesions and sebum production better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.